Eximis Surgical

Executive Summary

Eximis Surgical is a privately held medical device company founded in 2018 and headquartered in Austin, Texas. The company is developing a novel, fully contained device platform designed to enable minimally invasive specimen removal during laparoscopic surgery. Currently, surgeons often need to enlarge small incisions at the end of procedures to extract larger tissue samples, partially negating the benefits of minimally invasive surgery. Eximis’s technology aims to eliminate this step, potentially reducing patient trauma, recovery time, and scarring. The device is still in development, and the company is actively working toward regulatory clearance and commercialization. Given the strong clinical need for improved surgical tools and the increasing adoption of laparoscopic techniques, Eximis Surgical is positioned to address a significant unmet need. The company’s solution could become a standard adjunct in laparoscopic procedures, appealing to both surgeons and hospitals seeking better patient outcomes. However, as a development-stage company, Eximis faces typical risks including capital requirements, regulatory hurdles, and competition. Its success will hinge on achieving regulatory milestones, securing additional funding, and forming strategic partnerships. With a clear value proposition and a focused product pipeline, Eximis represents a compelling opportunity in the surgical device space.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for initial device70% success
• Q4 2026Series A or B funding round completion80% success
• Q2 2027Clinical study results demonstrating safety and efficacy60% success